Results 21 to 30 of about 37,267 (288)
Prognosis and Staging of AL Amyloidosis [PDF]
Acta Haematologica, 2020 The treatment options for systemic light chain amyloidosis (AL) are currently widening in an unprecedented way, brought about by an expanding arsenal of anti-myeloma therapy as well as by novel approaches to target toxic light chains and, most recently, deposited amyloid directly.
Tobias Dittrich +3 more
openaire +2 more sources
Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis
Swiss Medical Weekly, 2020 Systemic amyloidosis is a heterogeneous group of diseases associated with protein misfolding into insoluble beta-sheet rich structures that deposit extracellularly in different organs, eventually compromising their function.
Rahel Schwotzer +42 more
doaj +1 more source
Dysregulation of miRNAs In AL Amyloidosis [PDF]
Blood, 2010 Abstract Abstract 4648 Bone marrow plasma cells (BMPC) were purified from aspirates obtained from patients with AL amyloidosis using anti-CD138 immunomagnetic beads, and from controls. Expression levels of micro RNAs (miRNAs) were compared by microarray.
Carl O'Hara +5 more
openaire +4 more sources
Strong positive light chain immunostaining in a patient with transthyretin amyloidosis
Hematology, 2023 The two most common systemic amyloidosis types are immunoglobulin light chain (AL) and amyloid transthyretin (ATTR) amyloidosis, in which the precursor proteins responsible for amyloidosis are light chain and transthyretin, respectively.
Jiao Chen +5 more
doaj +1 more source
Dermatologica Sinica, 2018 Mucocutaneous lesion appears in up to 40% of patients with primary systemic amyloidosis (AL amyloidosis). The cutaneous signs may be co-expressed with other organ involvement or even solely presented as the first clue.
Yin-Shuo Chang +4 more
doaj +1 more source
JACC: Case Reports, 2021 Currently adopted diagnostic flow charts consider transthyretin and light-chain cardiac amyloidosis as mutually exclusive. Here, we report for the first time, to our knowledge, the demonstration of a biopsy-proven dual pathology in an 80-year-old man ...
Giuseppe Vergaro, MD, PhD +9 more
doaj
Journal of Medical Science, 2016 Amyloidosis is a heterogeneous group of disorders associated with pathological deposition of amyloid. We can recognize two major categories of amyloidosis: primary (AL) and secondary (AA) type.
Agnieszka Danuta Gaczkowska +2 more
doaj +1 more source
Korean Journal of Transplantation, 2020 Amyloid light-chain (AL) amyloidosis after kidney transplantation is a rare disease in the world, and only one case of systemic AL amyloidosis after kidney transplantation is reported in Korea.
Sung Hyun Park +8 more
doaj +1 more source
Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis
Therapeutic Advances in Hematology, 2021 Primary systemic immunoglobulin light chain (AL) amyloidosis is caused by a plasma cell clone of, usually low, malignant potential that expresses CD38 molecules on their surface.
Foteini Theodorakakou +2 more
doaj +1 more source
Evaluation of peripheral amyloid neuropathy
Неврология, нейропсихиатрия, психосоматика, 2021 Symptoms of peripheral nervous system (PNS) damage are common clinical manifestations of systemic amyloidosis. Peripheral amyloid neuropathy is characterized by a progressive course, leading to the disability of patients; however, the current ...
O. E. Zinovyeva +4 more
doaj +1 more source